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Abstract 
 
We train a neural network to predict human gene expression levels based on experimental data 
for rat cells.  The network is trained with paired human/rat samples from the Open TG-GATES 
database, where paired samples were treated with the same compound at the same dose.  
When evaluated on a test set of held out compounds, the network successfully predicts human 
expression levels.  On the majority of the test compounds, the list of differentially expressed 
genes determined from predicted expression levels agrees well with the list of differentially 
expressed genes determined from actual human experimental data. 
 
Introduction 
 
An important problem in biomedical research is to predict the result of an experiment on one 
species based on experiments conducted on a different species.  This is especially vital in 
preclinical pharmaceutical research.  Due to the cost, ethical issues, and time requirements of 
testing drug candidates on humans, they are first tested on animals and only advanced to 
clinical trials if the results are sufficiently promising.  Unfortunately, laboratory animals are often 
a poor proxy for humans [1].  For example, a drug that appears safe in rodents may turn out to 
be highly toxic in humans [2], and vice versa.  One cannot assume humans will respond in 
exactly the same way as test animals.  Instead, we view the data collected from animal 
experiments as raw data, then seek to predict the result of conducting a similar experiment on 
humans, taking the many biological differences into account. 
 
A closely related problem is to predict the result of in vivo experiments based on data from in 
vitro experiments with cell cultures or organoids [3].  A human cell line is very different from a 
live human, and its response to a chemical may be very different.  The goal is to use the data 
from in vitro experiments to predict how a human would respond, taking all of the biological 
differences into account. 
 
In this study, we consider the particular problem of trying to predict gene expression levels.  For 
example, given expression data for a rat treated with a particular drug, predict how that same 
drug would affect expression levels in a human.  Software for doing this sort of prediction has 
existed for some years [4], but it has generally worked in a very primitive way based only on 
homology.  For every gene in the target organism, it looks for an ortholog in the source 
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organism then assumes the two genes would have identical expression levels.  This takes none 
of the biological differences between organisms into account. 
 
A more recent study tried to improve on this by filtering the list of orthologs to only those 
displaying a consistent, monotonic dose response in both species [5].  The results show that 
translating expression between species is possible, but also demonstrate the limited power of 
this approach.  The predictive genes varied between compounds, and for some compounds no 
predictive genes at all were identified.  Simply copying expression values between orthologs is 
clearly not a reliable technique. 
 
In this study we try a different approach, using machine learning to train a neural network that 
can translate full expression profiles between species.  We use expression data from the Open 
TG-GATES database [6] for rat and human liver cells treated with various compounds.  
Samples are paired that share the same compound, dose, and time point.  Approximately 90% 
of the data (1024 rat/human sample pairs for 125 compounds) is used to train a neural network 
that takes rat expression levels as input and produces human expression levels as output.  The 
remainder of the data (98 rat/human sample pairs for 14 other compounds) is set aside as a test 
set.  The result is a model that can take arbitrary rat expression profiles as input and predict a 
complete expression profile for human cells treated with the same compound at the same dose. 
 
This work should be viewed as a proof of concept.  Ideally we would like to predict the effect of 
a drug in vivo, but because Open TG-GATES only provides in vitro data for humans, we were 
unable to test that.  In principle the model and training procedure described here should be 
equally applicable to any type of expression data, whether for cell lines, organoids, or living 
organisms.  One simply needs a sufficient set of paired experimental samples to train it on. 
 
Results 
 
Prediction Accuracy 
 
We can evaluate the accuracy of the model by feeding rat expression levels into it, then 
comparing the predicted human expression levels ypred to those which were actually measured 
in the corresponding experiment on human cells ytrue.  Figure 1 shows a scatterplot of the 
predicted vs. real expression levels for a typical sample in the test set.  There is a strong linear 
correlation between the two, showing the model has successfully learned something.  Over the 
entire test set (a total of 1,994,496 measurements), the real and predicted expression levels 
have a correlation coefficient of 0.697 and a mean absolute error (MAE) of 0.158.  There is 
considerable variation in accuracy between samples.  Over the 98 samples in the test set, the 
correlation coefficient ranges from 0.104 to 0.929, with a median of 0.791.  The MAE ranges 
from 0.098 to 0.320, with a median of 0.139.  We will return later to the question of why the 
predictions are more accurate for some samples than others. 
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Figure 1.  Predicted vs. experimental expression levels for all human genes in a representative 
sample from the test set. 
 
Ideally one would like to know in advance which values are most accurate.  In addition to 
predicting the expression level of every human gene, the neural network is also trained to 
estimate the standard deviation in each of its output values.  Assuming these estimates are 
accurate, this allows a user to assess the reliability of conclusions drawn from the predicted 
expression levels.  Figure 2 shows a scatterplot and heat map of the true error ypred-ytrue versus 
the predicted standard deviation σpred for every gene in a typical test sample.  There is a clear 
connection between the two, with the error magnitude growing with σpred.  For genes that are 
predicted to have a small standard deviation (those at the left edge of the scatterplot), the true 
error is consistently small. 
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Figure 2.  True error versus predicted standard deviation for all human genes in a 
representative sample from the test set.  The heat map (right) emphasizes that most genes fall 
in the low-error region of the plot. 
 
Figure 3 shows a histogram of |ypred-ytrue|/σpred, the absolute error measured in units of the 
predicted standard deviation, over all data points in the test set.  Most predicted expression 
levels are within a few standard deviations of the true value, although the distribution clearly 
decays more slowly than a normal distribution.  This again demonstrates that the predicted 
standard deviations provide useful information about the accuracy of predicted expression 
levels. 
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Figure 3.  Histogram of the absolute error in expression values, measured in units of the 
predicted standard deviation. 
 
Now consider the variation in error between samples.  Figure 4 shows a scatterplot of MAE 
versus mean predicted standard deviation for the 98 samples in the test set.  There is some 
correlation between the two, but it is fairly weak (correlation coefficient 0.17).  The predicted 
uncertainties appear to be less useful for judging the relative accuracies of samples than they 
are for judging the relative accuracies of genes within a single sample. 
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Figure 4.  Mean absolute error versus mean predicted standard deviation for the 98 samples in 
the test set.  Means are taken over all the genes for which we have expression data. 
 
In summary, the predicted uncertainties are a useful tool that provides insight into the likely 
range of each value, but they must be interpreted cautiously.  One should be especially careful 
about using them in statistical tests as if they were true standard deviations.  They are only 
estimates and cannot form the basis of a rigorous statistical analysis. 
 
Differentially Expressed Genes 
 
For most practical purposes, the ultimate test of predicted expression levels is whether they can 
be used to identify differentially expressed genes.  We evaluate this by computing a list of the 
100 most highly differentially expressed genes for each of the 14 compounds in the test set.  
For each one we compare the earliest time point (2 or 8 hours) control sample to the latest time 
point (24 hours), highest dose sample.  Genes are ranked based on the absolute difference in 
their normalized log scale expression levels between these two samples.  This analysis is 
performed twice: once for the experimental data on human cells, and once for the predicted 
human expression levels based on experimental rat data. 
 
This is, of course, a very simple way of identifying differentially expressed genes.  In practice 
one would typically use a more sophisticated statistical analysis that takes into account all dose 
levels and time points.  For our present purposes, we just need a simple analysis that can be 
applied in a consistent way for all compounds.  We seek a qualitative answer to the question of 
whether the model’s predictions provide useful information about which human genes are most 
affected by each compound. 
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Table 1 compares the two lists of genes for each compound (one based on true data and one 
based on predicted data) and shows how many genes they have in common.  The number 
varies from only 6 of 100 genes for papaverine, up to 85 of 100 genes for tamoxifen.  For 8 of 
the 14 test compounds, the two lists share the majority of their genes in common.  Note that if 
the genes were chosen completely randomly, we would expect the average number of common 
genes to be less than one.  Having even 6 genes in common therefore indicates that the model 
is producing significant information about the true list of genes, although it might not be enough 
information to be useful for a particular purpose. 
 
Compound # Genes 
acarbose 63 
aspirin 66 
chloramphenicol 59 
danazol 13 
diltiazem 59 
famotidine 69 
furosemide 15 
hydroxyzine 53 
imipramine 55 
methapyrilene 7 
papaverine 6 
promethazine 36 
tamoxifen 85 
tunicamycin 12 
 
Table 1.  The number of the top 100 differentially expressed genes in common between the 
experimental and predicted expression levels. 
 
We now consider why the results are more accurate for some compounds than others.  
Generally speaking, any machine learning model will tend to be most accurate when used on 
data similar to the data it was trained on.  This suggests two hypotheses for why our neural 
network produces more accurate results for some compounds than others. 
 
Hypothesis 1.  Some compounds affect expression levels in ways that are very different from 
those in the training set, leading to a reduction in accuracy on those compounds.  If this 
hypothesis is correct, we should expect to see a dose effect.  The control samples for those 
compounds should have no more error than any other sample, but the error should increase 
with dose. 
 
Hypothesis 2.  There may have been differences in experimental conditions unrelated to the 
particular compound being tested.  The Open TG-GATES data was generated by multiple 
organizations over a period of ten years.  Efforts were made to keep experimental conditions 
consistent, but some variation was inevitable.  If this hypothesis is correct, we should expect to 
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see unusually large errors in the control samples for some compounds, even though all control 
samples should in principle be equivalent. 
 
Figure 5 shows how the MAE varies with both compound and dose.  We see that the 
compounds divide into a few categories. 
 
 
Figure 5.  Mean absolute error in predicted expression level versus compound and dose.  The 
values shown are for the 24 hour time points.  Means are taken over all genes for each sample. 
 
First, some compounds display a consistently low error level and little or no variation with dose.  
Examples include chloramphenicol, diltiazem, famotidine, imipramine, and tamoxifen.  All of 
these are compounds for which the majority of the top 100 differentially expressed genes were 
identical between the true and predicted data. 
 
Second, some compounds display a clear dose effect.  Examples include furosemide, 
methapyrilene, and papaverine.  The control samples for these compounds have similar error to 
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most other control samples, but the error increases sharply with dose.  A possible explanation is 
that these compounds produce changes in gene expression that are significantly different from 
most of the training compounds, leading to less accurate (though still meaningful) predictions. 
 
Finally, there are a few cases where even the control samples have unusually high error: 
promethazine, and to a lesser extent danazol and tunicamycin.  In principle all control samples 
should be interchangeable.  The fact that they are not suggests some other source of variation 
in the data unrelated to the particular compound being tested.  It is difficult to guess what factor 
or factors might be responsible.  This serves as an important reminder that any machine 
learning model can only be as good as the data it is trained with and tested on. 
 
Saliency Mapping 
 
For some purposes a neural network can be treated as a black box that produces numbers.  In 
other cases, it is useful to understand something about how it works.  What input features led to 
a particular prediction? 
 
With a linear model, we could answer this question simply by looking at the weights.  Every 
output value would be a linear combination of input values, so we could directly read off how 
much each one contributed.  A neural network is a nonlinear model, so this is not possible, but 
we can still form a linear approximation to it.  Given a particular input sample, we compute the 
derivative of each output with respect to each input.  In the field of computer vision, this 
technique is known as saliency mapping [7].  For a given output gene, we refer to the absolute 
value of its derivative with respect to each input gene as the input gene’s saliency.  It tells us 
how sensitive the output is to the level of each rat gene. 
 
We might hope to find that each human gene depends only on a few rat genes, primarily on 
orthologs.  This would make the model easy to interpret and vindicate the traditional approach 
of performing translation based on homology.  In practice this is not what we find.  Instead, the 
predicted expression level for each human gene is the sum of small contributions from a large 
number of rat genes.  On average, the saliency of the most important rat gene is only about 
twice that of the 50th most important one.  Each output prediction is weakly influenced by 
dozens of input values. 
 
This result is not surprising.  It is well known that expression levels for different genes are highly 
correlated.  For example, it has been shown that given the expression levels of only about 1000 
carefully chosen “landmark genes”, it is possible to predict the expression levels of the 
remaining ~21,000 genes in the human genome [8].  Given many highly correlated input 
features to work with, one should expect the training procedure to select a model that averages 
over many of them, since this will produce much less noise than using only a few of them. 
 
Methods 
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To create the training and test datasets, we began with all in vitro human and rat liver samples 
from Open TG-GATES.  RMA normalization [9] was performed with the pyAffy library [10], using 
the Rat2302_Rn_ENTREZG_22.0.0 and HGU133Plus2_Hs_ENTREZG_22.0.0 CDF files from 
the BrainArray website [11].  These are custom GeneChip array definition files that correct a 
variety of problems found in the original definitions created by Affymetrix.  They define a total of 
14,075 rat genes and 20,352 human genes, each corresponding to a unique Entrez Gene ID 
[12]. 
 
Rat and human arrays were matched up based on compound, dose, and time point.  The 
normalized expression values for the two replicate samples for each condition were averaged.  
This produced a total of 1122 pairs of corresponding rat and human expression profiles.  These 
were split by compound into training and test sets as described previously. 
 
The mean expression level of each gene over the training set was subtracted from all the data 
(both training and test sets).  This is simply a constant shift which in principle the neural network 
could learn on its own.  In practice, we found that centering the data around zero made the 
learning problem easier and improved the results. 
 
Our model is a fully connected neural network with one hidden layer of width 20,000 and 
rectified linear unit activation [13].  It was trained for 1000 epochs with an Adam optimizer [14] 
and a batch size of 100.  The learning rate was initially set to 0.0001, then decayed by 
multiplying it by 0.9 every 200 steps.  50% dropout was used for regularization [15]. 
 
Uncertainty estimation was implemented as described in [16].  This involves two distinct types of 
uncertainty that are calculated in different ways, then combined to produce a single estimate of 
the total uncertainty. 
 
● Aleatoric uncertainty refers to the fact that the model does not perfectly fit the training 
data.  It is computed by having the model output an uncertainty estimate for every value 
it predicts, and using an appropriate loss function to encourage accurate estimates. 
● Epistemic uncertainty refers to the fact that multiple models can fit the training data 
equally well, but they produce different predictions for test data.  It is computed by 
performing prediction many times (50 in this work) with different dropout masks, then 
computing the variation in output. 
 
The model was implemented with DeepChem 1.2 [17] and TensorFlow 1.9 [18].  Source code 
for building and training the model is included in the supporting information. 
 
Discussion 
 
This study is a proof of concept that a neural network can predict gene expression levels in one 
species based on experimental data from a different species.  In this case, we predict in vitro 
human expression based on in vitro rat expression.  The method should be equally applicable 
for any pair of species, and also for in vivo data.  For example, it could be used to predict the 
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clinical effect of a drug candidate based on experimental data from human cell lines or 
organoids.  One simply needs a collection of paired expression profiles to train it on, and the 
model will learn whatever predictive information is present in the training data.  It also could be 
used to predict the effects of other types of factors: environmental conditions, mutations, etc. 
 
The accuracy of the predicted expression levels varies between samples, but in many cases it is 
excellent.  For the majority of the held out compounds used as a test set, the list of differentially 
expressed genes identified from the predicted data is very similar to the list identified from 
actual experimental data.  For other compounds the accuracy is lower, but even then the 
overlap in differentially expressed genes is much greater than would be expected by chance, 
showing that the model is still producing meaningful information. 
 
As with any machine learning model, the size and quality of the training dataset is critical.  A 
neural network is essentially a way of performing interpolation and extrapolation from existing 
data.  The further it needs to extrapolate, the less accurate its predictions are likely to be.  For 
this study we use the Open TG-GATES database, which contains in vitro rat and human data, 
as well as in vivo rat data.  Ideally we would like to predict the clinical effects of a drug candidate 
based on preclinical data, but since Open TG-GATES lacks in vivo human data, we were unable 
to test that.  For practical applications of this method, the identification or creation of suitable 
training datasets is the primary challenge that must be overcome. 
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